

# Esteban Dauden

## List of Publications by Year in descending order

Source: <https://exaly.com/author-pdf/2718511/publications.pdf>

Version: 2024-02-01

113  
papers

2,504  
citations

218381

26  
h-index

233125

45  
g-index

119  
all docs

119  
docs citations

119  
times ranked

2799  
citing authors

| #  | ARTICLE   | IF  | CITATIONS |
|----|---|-----|-----------|
| 1  | European S3â€œGuidelines on the systemic treatment of psoriasis vulgaris â€œ Update 2015 â€œ Short version â€œ <scp>EDF</scp> in cooperation with <scp>EADV</scp> and <scp>IPC</scp>. Journal of the European Academy of Dermatology and Venereology, 2015, 29, 2277-2294.    | 1.3 | 353       |
| 2  | Critical role of interleukin (IL)-17 in inflammatory and immune disorders: An updated review of the evidence focusing in controversies. Autoimmunity Reviews, 2020, 19, 102429.   | 2.5 | 197       |
| 3  | European S3â€œGuideline on the systemic treatment of psoriasis vulgaris â€œ Update Apremilast and Secukinumab â€œ <scp>EDF</scp> in cooperation with <scp>EADV</scp> and <scp>IPC</scp>. Journal of the European Academy of Dermatology and Venereology, 2017, 31, 1951-1963. | 1.3 | 116       |
| 4  | Consensus document on the evaluation and treatment of moderateâ€œtoâ€œsevere psoriasis: Psoriasis Group of the Spanish Academy of Dermatology and Venereology. Journal of the European Academy of Dermatology and Venereology, 2016, 30, 1-18.                                | 1.3 | 105       |
| 5  | Improvements in patient-reported outcomes in moderate-to-severe psoriasis patients receiving continuous or paused etanercept treatment over 54 weeks: the CRYSTEL study. Journal of the European Academy of Dermatology and Venereology, 2009, 23, 1374-1382.                 | 1.3 | 88        |
| 6  | Drug Survival of IL-12/23, IL-17 and IL-23 Inhibitors for Psoriasis Treatment: A Retrospective Multi-Country, Multicentric Cohort Study. American Journal of Clinical Dermatology, 2021, 22, 567-579.   | 3.3 | 65        |
| 7  | Position statement for the management of comorbidities in psoriasis. Journal of the European Academy of Dermatology and Venereology, 2018, 32, 2058-2073.   | 1.3 | 61        |
| 8  | Calciophylaxis. Dermatologic Clinics, 2008, 26, 557-568.  | 1.0 | 56        |
| 9  | Helicobacter pylori and idiopathic chronic urticaria. International Journal of Dermatology, 2000, 39, 446-452.  | 0.5 | 54        |
| 10 | Histone modifications associated with biological drug response in moderateâ€œtoâ€œsevere psoriasis. Experimental Dermatology, 2018, 27, 1361-1371.  | 1.4 | 48        |
| 11 | Thrombotic occlusive vasculopathy in a skin biopsy from a livedoid lesion of a patient with <scp>COVID</scp> â€œ19. British Journal of Dermatology, 2020, 183, 591-593.   | 1.4 | 47        |
| 12 | The polymorphism rs763780 in the <i>IL-17F</i> gene is associated with response to biological drugs in patients with psoriasis. Pharmacogenomics, 2015, 16, 1723-1731.  | 0.6 | 45        |
| 13 | Paradoxical psoriasiform reactions to anti-TNFÎ± drugs are associated with genetic polymorphisms in patients with psoriasis. Pharmacogenomics Journal, 2016, 16, 336-340.   | 0.9 | 45        |
| 14 | Efficacy and safety of continuous versus paused etanercept treatment in patients with moderate-to-severe psoriasis over 54 weeks: the CRYSTEL study. Expert Review of Dermatology, 2008, 3, 657-665.  | 0.3 | 44        |
| 15 | Recommendations for the management of comorbidity in hidradenitis suppurativa. Journal of the European Academy of Dermatology and Venereology, 2018, 32, 129-144.   | 1.3 | 43        |
| 16 | Psoriasis y depresiÃ³n: el papel de la inflamaciÃ³n. Actas Dermo-sifiliogrÃ¡ficas, 2019, 110, 12-19.  | 0.2 | 43        |
| 17 | PAPULAR-PURPURIC GLOVES-AND-SOCKS SYNDROME. International Journal of Dermatology, 1996, 35, 626-632.  | 0.5 | 41        |
| 18 | Pharmacogenetics and Pharmacogenomics in Moderate-to-Severe Psoriasis. American Journal of Clinical Dermatology, 2018, 19, 209-222.   | 3.3 | 39        |

| #  | ARTICLE   | IF  | CITATIONS |
|----|---|-----|-----------|
| 19 | Mucocutaneous presence of cytomegalovirus associated with human immunodeficiency virus infection: discussion regarding its pathogenetic role. Archives of Dermatology, 2001, 137, 443-8.  | 1.7 | 38        |
| 20 | Metotrexato en psoriasis moderada-grave: revisi3n de la literatura y recomendaciones de experto. Actas Dermo-sifilogr4ficas, 2016, 107, 194-206.  | 0.2 | 37        |
| 21 | Long-term safety of nine systemic medications for psoriasis: A cohort study using the Spanish Registry of Adverse Events for Biological Therapy in Dermatological Diseases (BIOBADADERM) Registry. Journal of the American Academy of Dermatology, 2020, 83, 139-150.   | 0.6 | 37        |
| 22 | Reply to "Varicella-like exanthem as a specific COVID-19-associated skin manifestation: Multicenter case series of 22 patients" To consider varicella-like exanthem associated with COVID-19, virus varicella zoster and virus herpes simplex must be ruled out. Journal of the American Academy of Dermatology, 2020, 83, e253-e254. | 0.6 | 35        |
| 23 | New polymorphisms associated with response to anti-TNF drugs in patients with moderate-to-severe plaque psoriasis. Pharmacogenomics Journal, 2018, 18, 70-75.   | 0.9 | 31        |
| 24 | CRYOGLOBULINEMIA AND CUTANEOUS LEUKOCYTOCLASTIC VASCULITIS WITH HEPATITIS C VIRUS INFECTION. International Journal of Dermatology, 1996, 35, 112-115.   | 0.5 | 29        |
| 25 | Pharmacogenetics of topical and systemic treatment of psoriasis. Pharmacogenomics, 2013, 14, 1623-1634.   | 0.6 | 29        |
| 26 | IL17RA gene variants and anti-TNF response among psoriasis patients. Pharmacogenomics Journal, 2018, 18, 76-80.   | 0.9 | 28        |
| 27 | Safety and effectiveness of conventional systemic therapy and biological drugs in patients with moderate to severe psoriasis and HIV infection: a retrospective multicenter study. Journal of Dermatological Treatment, 2019, 30, 461-465.  | 1.1 | 27        |
| 28 | Incidence of severe COVID-19 outcomes in psoriatic patients treated with systemic therapies during the pandemic: A Biobadaderm cohort analysis. Journal of the American Academy of Dermatology, 2021, 84, 513-517.  | 0.6 | 26        |
| 29 | Polymorphisms associated with etanercept response in moderate-to-severe plaque psoriasis. Pharmacogenomics, 2017, 18, 631-638.  | 0.6 | 25        |
| 30 | Pharmacogenetics of ustekinumab in patients with moderate-to-severe plaque psoriasis. Pharmacogenomics, 2017, 18, 157-164.  | 0.6 | 24        |
| 31 | An4lisis de la hepatotoxicidad en psoriasis tratada con ustekinumab. Estudio retrospectivo de 44 pacientes en pr4ctica cl4nica habitual. Actas Dermo-sifilogr4ficas, 2015, 106, 470-476.  | 0.2 | 23        |
| 32 | Expert recommendations: the use of the fixed combination calcipotriol and betamethasone dipropionate gel for the topical treatment of psoriasis. Journal of the European Academy of Dermatology and Venereology, 2014, 28, 22-32.   | 1.3 | 22        |
| 33 | Reformulations of well-known active ingredients in the topical treatment of psoriasis vulgaris can improve clinical outcomes for patients. Journal of the European Academy of Dermatology and Venereology, 2017, 31, 1271-1284.   | 1.3 | 21        |
| 34 | Polymorphisms associated with adalimumab and infliximab response in moderate-to-severe plaque psoriasis. Pharmacogenomics, 2018, 19, 7-16.  | 0.6 | 21        |
| 35 | Juvenile Psoriasis und ihre Behandlungsm4glichkeiten: Konsensus einer europ4ischen Expertengruppe. JDDG - Journal of the German Society of Dermatology, 2010, 8, 812-819.   | 0.4 | 20        |
| 36 | Secukinumab treatment leads to normalization of quality of life and disease symptoms in psoriasis patients with or without prior systemic psoriasis therapy: the PROSE study results. Journal of the European Academy of Dermatology and Venereology, 2021, 35, 431-440.  | 1.3 | 20        |

| #  | ARTICLE  | IF  | CITATIONS |
|----|--|-----|-----------|
| 37 | Adverse events associated with discontinuation of the biologics/classic systemic treatments for moderate-to-severe plaque psoriasis: data from the Spanish Biologics Registry, <i>Biobadaderm. Journal of the European Academy of Dermatology and Venereology</i> , 2017, 31, 1700-1708. | 1.3 | 19        |
| 38 | Thrombospondin-1/CD47 Interaction Regulates Th17 and Treg Differentiation in Psoriasis. <i>Frontiers in Immunology</i> , 2019, 10, 1268.   | 2.2 | 18        |
| 39 | Polymorphisms Associated with Age at Onset in Patients with Moderate-to-Severe Plaque Psoriasis. <i>Journal of Immunology Research</i> , 2015, 2015, 1-8.  | 0.9 | 17        |
| 40 | Plasma trough levels of mycophenolic acid do not correlate with efficacy and safety of mycophenolate mofetil in psoriasis. <i>British Journal of Dermatology</i> , 2004, 150, 132-135.   | 1.4 | 16        |
| 41 | Patient-relevant needs and treatment goals in nail psoriasis. <i>Quality of Life Research</i> , 2016, 25, 1179-1188.   | 1.5 | 16        |
| 42 | Psoriasis Therapy and Skin Cancer: A Review. <i>Life</i> , 2021, 11, 1109.   | 1.1 | 16        |
| 43 | Desmotivación del personal sanitario y síndrome de burnout. Control de las situaciones de tensión. La importancia del trabajo en equipo. <i>Actas Dermo-sifiligráficas</i> , 2016, 107, 400-406.   | 0.2 | 15        |
| 44 | Serie de casos de pacientes psoriásicas expuestas a terapia biológica durante el embarazo. Registro BIOBADADERM y revisión de la literatura. <i>Actas Dermo-sifiligráficas</i> , 2017, 108, 168-170.   | 0.2 | 15        |
| 45 | PASI 100 response rates in moderate to severe psoriasis: a systematic literature review and analysis of clinical practice guidelines. <i>Journal of Dermatological Treatment</i> , 2022, 33, 1661-1669.  | 1.1 | 15        |
| 46 | Development and Validation of a New Instrument to Measure Health-related Quality of Life in Patients with Psoriatic Arthritis: The VITACORA-19. <i>Journal of Rheumatology</i> , 2014, 41, 2008-2017.  | 1.0 | 14        |
| 47 | Bullous pemphigoid associated with dipeptidyl peptidase-4 inhibitors. A case series and analysis of cases reported in the Spanish pharmacovigilance database. <i>International Journal of Dermatology</i> , 2020, 59, 197-206.   | 0.5 | 14        |
| 48 | Effectiveness and satisfaction with imiquimod for the treatment of superficial basal cell carcinoma in daily dermatological practice. <i>Journal of the European Academy of Dermatology and Venereology</i> , 2011, 25, 1304-1310.   | 1.3 | 13        |
| 49 | Epigenetic biomarkers associated with antitumour necrosis factor drug response in moderate-to-severe psoriasis. <i>British Journal of Dermatology</i> , 2018, 178, 798-800.  | 1.4 | 13        |
| 50 | Polymorphisms associated with anti-TNF drugs response in patients with psoriasis and psoriatic arthritis. <i>Journal of the European Academy of Dermatology and Venereology</i> , 2019, 33, e175-e177.   | 1.3 | 13        |
| 51 | Reduced doses of biological therapies in psoriasis may increase efficiency without decreasing drug survival. <i>Dermatologic Therapy</i> , 2020, 33, e14134.   | 0.8 | 12        |
| 52 | Microscopic polyangiitis. A systemic vasculitis with a positive P-ANCA. <i>British Journal of Dermatology</i> , 1996, 134, 542-547.  | 1.4 | 11        |
| 53 | Genome-wide association analysis of psoriasis patients treated with anti-TNF drugs. <i>Experimental Dermatology</i> , 2020, 29, 1225-1232.   | 1.4 | 11        |
| 54 | Pharmacogenetics Update on Biologic Therapy in Psoriasis. <i>Medicina (Lithuania)</i> , 2020, 56, 719.   | 0.8 | 11        |

| #  | ARTICLE   | IF  | CITATIONS |
|----|---|-----|-----------|
| 55 | Utility of circulating serum miRNA profiles to evaluate the potential risk and severity of immune-mediated inflammatory disorders. <i>Journal of Autoimmunity</i> , 2020, 111, 102472.  | 3.0 | 11        |
| 56 | Growth arrest and DNA damage-inducible proteins (GADD45) in psoriasis. <i>Scientific Reports</i> , 2021, 11, 14579.   | 1.6 | 11        |
| 57 | Biosimilares en dermatología. Situación actual (parte i). <i>Actas Dermo-sifilográficas</i> , 2015, 106, 545-549.   | 0.2 | 10        |
| 58 | GATA3 staining in primary cutaneous apocrine cribriform carcinoma: Usefulness to differentiate it from breast cancer metastasis. <i>Journal of Cutaneous Pathology</i> , 2018, 45, 348-351.   | 0.7 | 10        |
| 59 | Expression of miR-135b in Psoriatic Skin and Its Association with Disease Improvement. <i>Cells</i> , 2020, 9, 1603.  | 1.8 | 10        |
| 60 | Baseline characteristics of patients with moderate-to-severe psoriasis according to previous systemic treatment exposure: the PROSE study population. <i>Journal of the European Academy of Dermatology and Venereology</i> , 2020, 34, 2548-2556.                                    | 1.3 | 10        |
| 61 | Impact of Active and Stable Psoriasis on Health-Related Quality of Life: The PSO-LIFE Study. <i>Actas Dermo-sifilográficas</i> , 2013, 104, 685-693.  | 0.2 | 8         |
| 62 | New immune system genetic polymorphisms associated with moderate-to-severe plaque psoriasis: a case-control study. <i>British Journal of Dermatology</i> , 2015, 172, 1432-1435.  | 1.4 | 8         |
| 63 | Expert consensus on the persistence of biological treatments in moderate-to-severe psoriasis. <i>Journal of the European Academy of Dermatology and Venereology</i> , 2019, 33, 1214-1223.  | 1.3 | 8         |
| 64 | Eccrine porocarcinoma with extensive cutaneous metastases. <i>International Journal of Dermatology</i> , 2016, 55, e156-60.   | 0.5 | 7         |
| 65 | Facial folliculocystic and collagen hamartoma: a variant of fibrous cephalic plaque with prominent cyst formation?. <i>JDDG - Journal of the German Society of Dermatology</i> , 2019, 17, 738-741.   | 0.4 | 7         |
| 66 | Polymorphisms associated with optimization of biological therapy through drug dose reduction in moderate-to-severe psoriasis. <i>Journal of the European Academy of Dermatology and Venereology</i> , 2020, 34, e271-e275.  | 1.3 | 7         |
| 67 | Mixed profile of cytokines in paradoxical eczematous eruptions associated with anti-IL-17 therapy. <i>Journal of Allergy and Clinical Immunology: in Practice</i> , 2020, 8, 3619-3621.e1.  | 2.0 | 7         |
| 68 | Tildrakizumab efficacy and safety in patients with psoriasis and concomitant metabolic syndrome: <i>post hoc</i> analysis of 5-year data from <i>reSURFACE</i> 1 and <i>reSURFACE</i> 2. <i>Journal of the European Academy of Dermatology and Venereology</i> , 2022, 36, 1774-1783. | 1.3 | 7         |
| 69 | Severe resistant subacute prurigo successfully controlled by long-term cyclosporin. <i>Journal of Dermatological Treatment</i> , 2003, 14, 48-50.   | 1.1 | 6         |
| 70 | Resolución de granuloma anular diseminado con fototerapia UVB de banda estrecha. <i>Actas Dermo-sifilográficas</i> , 2015, 106, 240-241.  | 0.2 | 6         |
| 71 | No evidence for induction of autoantibodies or autoimmunity during treatment of psoriasis with ustekinumab. <i>British Journal of Dermatology</i> , 2017, 177, 862-863.   | 1.4 | 6         |
| 72 | Change over time in the rates of adverse events in patients receiving systemic therapy for psoriasis: A cohort study. <i>Journal of the American Academy of Dermatology</i> , 2018, 78, 798-800.  | 0.6 | 6         |

| #  | ARTICLE  | IF  | CITATIONS |
|----|--|-----|-----------|
| 73 | Cambios en las tendencias de la prescripción y causas de la interrupción en los tratamientos biológicos indicados en la psoriasis durante los primeros 10 años. Datos obtenidos del registro español Biobadaderm. <i>Actas Dermo-sifiliográficas</i> , 2020, 111, 752-760.   | 0.2 | 6         |
| 74 | Multicenter Retrospective Study of Secukinumab Drug Survival in Psoriasis Patients in a Daily Practice Setting: A Long-Term Experience in Spain. <i>Dermatology and Therapy</i> , 2021, 11, 2207-2215.   | 1.4 | 6         |
| 75 | Differences in epidemiology, comorbidities and treatment choice between plaque psoriasis and pustular psoriasis: results from the BIOBADADERM registry. <i>British Journal of Dermatology</i> , 2022, 187, 817-820.  | 1.4 | 6         |
| 76 | Biosimilares en dermatología. Situación actual (parte ii). <i>Actas Dermo-sifiliográficas</i> , 2015, 106, 550-554.  | 0.2 | 5         |
| 77 | Inducción de anticuerpos y enfermedades autoinmunes en pacientes con psoriasis tratados con fármacos anti-TNF. <i>Actas Dermo-sifiliográficas</i> , 2017, 108, 445-456.  | 0.2 | 5         |
| 78 | Methylation in psoriasis. Does sex matter?. <i>Journal of the European Academy of Dermatology and Venereology</i> , 2021, 35, e161-e163.   | 1.3 | 5         |
| 79 | Food groups associated with immune-mediated inflammatory diseases: a Mendelian randomization and disease severity study. <i>European Journal of Clinical Nutrition</i> , 2021, 75, 1368-1382.  | 1.3 | 5         |
| 80 | Expression of microRNA-21 and TIMP-3 in paradoxical psoriasiform reactions during treatment with antitumor necrosis factor agents. <i>Journal of Cutaneous Pathology</i> , 2021, , .   | 0.7 | 5         |
| 81 | Etanercept for the treatment of psoriasis. <i>Expert Review of Dermatology</i> , 2013, 8, 357-372.   | 0.3 | 4         |
| 82 | Cutaneous side effects in a cohort of patients with chronic myeloid leukemia treated with tyrosine kinase inhibitors: General description and further characterization, correlation with photoexposure and study of hypopigmentation as treatment's prognostic factor. <i>Dermatologic Therapy</i> , 2020, 33, e14428. | 0.8 | 4         |
| 83 | The risk of hepatic adverse events of systemic medications for psoriasis: a prospective cohort study using the BIOBADADERM registry. <i>Journal of Dermatological Treatment</i> , 2022, 33, 2110-2117.   | 1.1 | 4         |
| 84 | Therapeutic goals and treatment response evaluation in moderate to severe psoriasis: an experts opinion document. <i>Annals of Medicine</i> , 2021, 53, 1727-1736.   | 1.5 | 4         |
| 85 | Sweet syndrome and differentiation syndrome in a patient with acute promyelocytic leukemia. <i>World Journal of Clinical Cases</i> , 2015, 3, 196.   | 0.3 | 3         |
| 86 | Poroqueratosis pruriginosa diseminada inflamatoria. Buena respuesta a ciclosporina. <i>Actas Dermo-sifiliográficas</i> , 2016, 107, 261-262.   | 0.2 | 3         |
| 87 | Detección precoz de la enfermedad psicoemocional en dermatología. <i>Actas Dermo-sifiliográficas</i> , 2016, 107, 294-300.   | 0.2 | 3         |
| 88 | Consensus Statement on the Management of Comorbidity in Patients with Rheumatoid Arthritis and Psoriasis. <i>Journal of Rheumatology</i> , 2016, 43, 990-991.  | 1.0 | 3         |
| 89 | Diagnostic approach to subcutaneous nodules in patients with neuroendocrine tumours treated with depot somatostatin analogs: a cross-sectional study. <i>Journal of the European Academy of Dermatology and Venereology</i> , 2018, 32, 1887-1892.   | 1.3 | 3         |
| 90 | Validación del método de cuantificación del área corporal afectada por la psoriasis mediante lámpiz láser. <i>Actas Dermo-sifiliográficas</i> , 2020, 111, 143-148.  | 0.2 | 3         |

| #   | ARTICLE  | IF  | CITATIONS |
|-----|--|-----|-----------|
| 91  | Association between eosinophilic folliculitis and follicular mucinosis. A case series. <i>International Journal of Dermatology</i> , 2020, 59, e376-e378.  | 0.5 | 3         |
| 92  | Epigenetics in Non-tumor Immune-Mediated Skin Diseases. <i>Molecular Diagnosis and Therapy</i> , 2021, 25, 137-161.  | 1.6 | 3         |
| 93  | Lymph node melanosis. Should it be managed as a high-risk melanoma? A case report and review of the literature. <i>Journal of the European Academy of Dermatology and Venereology</i> , 2016, 30, 511-513.                                   | 1.3 | 2         |
| 94  | Long-term treatment of neurofibromatosis 1 with ketotifen. A report of three cases. <i>American Journal of Medical Genetics, Part A</i> , 2016, 170, 1092-1094.  | 0.7 | 2         |
| 95  | Topical anticholinergic drugs in the treatment of multiple hidrocystomas: a crossover, randomized, double-blind, placebo-controlled study. <i>Journal of the European Academy of Dermatology and Venereology</i> , 2017, 31, e90-e92.        | 1.3 | 2         |
| 96  | Recalcitrant annular pustular psoriasis associated with psoriatic arthritis successfully treated with secukinumab. <i>JAAD Case Reports</i> , 2018, 4, 842-844.  | 0.4 | 2         |
| 97  | Consenso multidisciplinar sobre prevención y tratamiento de la tuberculosis en pacientes candidatos a tratamiento biológico. Adaptación al paciente dermatológico. <i>Actas Dermo-sifilográficas</i> , 2018, 109, 584-601.                   | 0.2 | 2         |
| 98  | [Translated article] Moderate to Severe Psoriasis in Pediatric and Young Patients: The BIOBADADERM Registry Experience. <i>Actas Dermo-sifilográficas</i> , 2022, 113, T401-T406.  | 0.2 | 2         |
| 99  | Atypical Ulcerated Lesions in a Patient With Cogan Syndrome. <i>Actas Dermo-sifilográficas</i> , 2017, 108, 369-371.   | 0.2 | 1         |
| 100 | Combination therapy of infliximab and ciclosporin in the treatment of recalcitrant psoriasis: a case series. <i>British Journal of Dermatology</i> , 2017, 176, 803-805.   | 1.4 | 1         |
| 101 | Tuberculosis screening in psoriatic patients under continuous biological therapy. Does the treatment modify the tuberculin skin test response?. <i>Journal of the European Academy of Dermatology and Venereology</i> , 2019, 33, e295-e296. | 1.3 | 1         |
| 102 | Launch and preliminary analysis of Hospital de La Princesa's inter-specialists biological therapies unit. <i>Reumatología Clínica</i> , 2019, 15, 63-68.   | 0.2 | 1         |
| 103 | Histopathologic study of paradoxical psoriasis induced by antitumor necrosis factor alpha therapy: Is it true psoriasis?. <i>Journal of Cutaneous Pathology</i> , 2021, 48, 813-816.   | 0.7 | 1         |
| 104 | Psoriasis moderada-grave en pacientes pediátricos y jóvenes: experiencia en el registro BIOBADADERM. <i>Actas Dermo-sifilográficas</i> , 2022, 113, 401-406.   | 0.2 | 1         |
| 105 | Fast and sustained Improvement of Patient-reported outcomes in psoriatic patients treated with secukinumab in a daily practice setting. <i>Dermatologic Therapy</i> , 0, , .   | 0.8 | 1         |
| 106 | Mucinosis nodular asociada a gammapatía monoclonal de cadenas ligeras de significado incierto. <i>Actas Dermo-sifilográficas</i> , 2017, 108, 272-273.   | 0.2 | 0         |
| 107 | Prevalence of amyloid deposits determined by fine-needle aspiration of abdominal fat in patients with psoriasis. <i>Journal of the European Academy of Dermatology and Venereology</i> , 2017, 31, e280-e281.                                | 1.3 | 0         |
| 108 | Calcinosis cutis facial en una paciente con dermatomiositis paraneoplásica. <i>Actas Dermo-sifilográficas</i> , 2018, 109, 760-762.  | 0.2 | 0         |

| #   | ARTICLE  | IF  | CITATIONS |
|-----|--|-----|-----------|
| 109 | Faziales follikul r cystisches und kollagenes Hamartom: eine Variante der fibr sen Stirnplaque mit prominenter Zystenbildung?. JDDG - Journal of the German Society of Dermatology, 2019, 17, 738-741. | 0.4 | 0         |
| 110 | Trough (C0) and 2-hour postdose (C2) cyclosporine monitoring in patients with moderate-to-severe psoriasis. Journal of the European Academy of Dermatology and Venereology, 2019, 33, e215-e217.       | 1.3 | 0         |
| 111 | Bilateral Facial Apocrine Fibrosing Hamartoma Mimicking Microcystic Adnexal Carcinoma. American Journal of Dermatopathology, 2019, 41, 767-770.  | 0.3 | 0         |
| 112 | A retrospective, observational multicenter study of 141 patients treated with ustekinumab 90 mg. Dermatologic Therapy, 2020, 33, e13678.   | 0.8 | 0         |
| 113 | Cutaneous vascular calcification. Perieccrine calcification as a diagnostic key for calciphylaxis. Journal of Cutaneous Pathology, 2022, 49, 683-691.  | 0.7 | 0         |